- * Men or women, at least 18 years of age, with evidence of myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI), in the last week.
Coagulation Protein Disorders
Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)
NCT01053169 | PHASE 2 | OBSERVATIONAL
Beriplex® P/N is made from human plasma (the liquid part of the blood) and contains the coagulation factors II, VII, IX and X which are important for blood clotting (coagulation). Lack of any of these factors means that blood does not clot as quickly as it should and so there is an increased tendency to bleed. This observational study was designed to evaluate the effectiveness of Beriplex® P/N in the prevention (prophylaxis) and treatment of bleeding during surgery (perioperative bleeding) in a routine clinical setting.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Royal Blackburn Hospital
Blackburn,United Kingdom
Blackpool
Blackpool,United Kingdom,FY38NR
Addenbrokes
Cambridge,United Kingdom,CB233RE
Royal Free Hospital
London,United Kingdom
Derriford Hospital
Plymouth,United Kingdom
Southhampton General Hospital
Southhampton,United Kingdom
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov